RudaCure ha completado the expansion of its Seoul office, which began on July 18th.
The Seoul office, spanning a total of 145 pyeong (aproximadamente 480 m²), ha sido relocated with the Clinical Team at its core along with the in vitro analysis team. Como resultado, the existing sede central in Songdo will focus on in vivo eficacia testing and internal pipeline investigación, while the Seoul office realizará MoA analysis alongside FLIPR services.
With the expansion of the business premises, la empresa will reorganize its investigación structure and strengthen its internal capabilities by reinforcing the investigación team. Through organizational restructuring, the plan is to accelerate both nacional e internacional ensayo clínicos for RCI001 while simultaneously strengthening new pipelines.
The Seoul office is located at Ace Hi-End 3rd Building, Suite 1001, Gasan Digital Complex.
